Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Levy

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk FactorsKarthik Suresh, Khinh Ranh Voong, Bairavi Shankar, et al.
The Journal of Clinical Investigation|July 17, 2019
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitisKarthik Suresh, Jarushka Naidoo, Qiong Zhong, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancerJoseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung CancerJoseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Nature Cancer|September 28, 2020
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancerValsamo Anagnostou, Noushin Niknafs, Kristen Marrone, et al.
Cancer Research|December 14, 2018
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung CancerValsamo Anagnostou, Patrick M Forde, James R White, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 10, 2025
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025Gregory J Riely, Douglas E Wood, Dara L Aisner, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2026
Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyGregory J Riely, Douglas E Wood, Dara L Aisner, et al.
Nature|February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk FactorsKarthik Suresh, Khinh Ranh Voong, Bairavi Shankar, et al.
The Journal of Clinical Investigation|July 17, 2019
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitisKarthik Suresh, Jarushka Naidoo, Qiong Zhong, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancerJoseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung CancerJoseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Nature Cancer|September 28, 2020
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancerValsamo Anagnostou, Noushin Niknafs, Kristen Marrone, et al.
Cancer Research|December 14, 2018
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung CancerValsamo Anagnostou, Patrick M Forde, James R White, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 10, 2025
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025Gregory J Riely, Douglas E Wood, Dara L Aisner, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2026
Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyGregory J Riely, Douglas E Wood, Dara L Aisner, et al.
Nature|February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 8